Skip to main content
Regeneron10-K: Cost reduction

Libtayo royalty rate to Bristol-Myers Squibb drops from 8.0% to 2.5% from 2024-2026.

What happened

A licensing agreement modification has significantly lowered the royalty payments on worldwide sales of Libtayo from 8.0% to 2.5%. This provides a direct boost to the product's gross margin and the company's overall profitability for a three-year period starting January 1, 2024.

Source

SEC EDGARFeb 4, 2026

Annual report (Form 10-K)

Regeneron 10-K for FY2025

Filing excerpt

Under the agreement, we paid royalties of 8.0% on worldwide sales of Libtayo through December 31, 2023, and are obligated to pay royalties of 2.5% from January 1, 2024 through December 31, 2026.

sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htmRead the full source

Other signals in this filing (4)

Extracted by Autobound

From the Signal API record
Signal
10-K: Cost reduction

What this signalsFilings often name leadership changes, deals and spending plans.

Period
FY2025
Fiscal year end
12/31
Filed
Feb 4, 2026

More 10-K signals at other companies

The full record

From the Signal API record

Numbers

Percent
5.5% (royalty rate reduction on worldwide Libtayo sales (from 8.0% to 2.5%))

Details

CIK
872589
Accession number
0000872589-26-000008
Timeframe
Multi year
Filing year
2026
Why it matters
Efficiency tools needed
Signal category
Financial

Topics and mentions

Vendors

  • Bristol-Myers Squibb
  • E. R. Squibb & Sons
  • L.L.C.
  • Ono Pharmaceutical Co.
  • Ltd.

Vendors named

  • Bristol-Myers Squibb
  • E. R. Squibb & Sons, L.L.C.
  • Ono Pharmaceutical Co., Ltd.

Extraction

Confidence
High
Relevance
90%
Sentiment
Positive
Detected
Feb 10, 2026
signal_type
sec-10k
signal_subtype
costReduction

Use this data

Get every 10-K signal for Regeneron and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Regeneron this week?”

  2. Send it to your own tools

    The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/e0212a14-9ee6-4e02-8408-85fa306b2fbe returns this record as JSON. POST /v1/companies/enrich returns every signal for regeneron.com.

{
  "signal_id": "e0212a14-9ee6-4e02-8408-85fa306b2fbe",
  "signal_type": "sec-10k",
  "signal_subtype": "costReduction",
  "detected_at": "2026-02-10T07:49:34.287+00:00",
  "company": {
    "name": "Regeneron",
    "domain": "regeneron.com"
  },
  "data": {
    "detail": "A licensing agreement modification has significantly lowered the royalty payments on worldwide sales of Libtayo from 8.0% to 2.5%. This provides a direct boost to the product's gross margin and the company's overall profitability for a three-year period starting January 1, 2024.",
    "metrics": {
      "pct": 5.5,
      "timeframe": "multi_year",
      "pct_context": "royalty rate reduction on worldwide Libtayo sales (from 8.0% to 2.5%)"
    },
    "summary": "Libtayo royalty rate to Bristol-Myers Squibb drops from 8.0% to 2.5% from 2024-2026.",
    "excerpts": "Under the agreement, we paid royalties of 8.0% on worldwide sales of Libtayo through December 31, 2023, and are obligated to pay royalties of 2.5% from January 1, 2024 through December 31, 2026.",
    "relevance": 0.9,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm",
    "filing_date": "2026-02-04",
    "filing_year": 2026,
    "fiscal_year_end": "12/31",
    "sales_relevance": "Efficiency tools needed",
    "signal_category": "financial",
    "vendors_mentioned": [
      "Bristol-Myers Squibb",
      "E. R. Squibb & Sons, L.L.C.",
      "Ono Pharmaceutical Co., Ltd."
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.